200 reports of this reaction
1.6% of all SCOPOLAMINE reports
#15 most reported adverse reaction
MYDRIASIS is the #15 most commonly reported adverse reaction for SCOPOLAMINE, manufactured by Baxter Healthcare Corporation. There are 200 FDA adverse event reports linking SCOPOLAMINE to MYDRIASIS. This represents approximately 1.6% of all 12,807 adverse event reports for this drug.
Patients taking SCOPOLAMINE who experience mydriasis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MYDRIASIS is a less commonly reported adverse event for SCOPOLAMINE, but still significant enough to appear in the safety profile.
In addition to mydriasis, the following adverse reactions have been reported for SCOPOLAMINE:
The following drugs have also been linked to mydriasis in FDA adverse event reports:
MYDRIASIS has been reported as an adverse event in 200 FDA reports for SCOPOLAMINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
MYDRIASIS accounts for approximately 1.6% of all adverse event reports for SCOPOLAMINE, making it a notable side effect.
If you experience mydriasis while taking SCOPOLAMINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.